Matthew P. Goetz, MD

Matthew P. Goetz, MD, is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic in Rochester, MN. Dr Goetz joined the staff at Mayo Clinic in 2003 and holds the academic rank of professor of oncology and pharmacology, Mayo Clinic College of Medicine and Science. He is recognized with the distinction of the Erivan K. Haub Family Professorship in Cancer Research Honoring Richard F. Emslander, M.D.

Dr Goetz leads breast cancer research activities at Mayo Clinic, where he is co-chair of the Mayo Breast Cancer Disease Group, coleader of the Women’s Cancer Program, and director of the Mayo Breast Cancer Specialized Programs of Research Excellence. Additionally, he is enterprise deputy director of translational research within the Mayo Clinic Comprehensive Cancer Center.  

He has been extensively involved in both translational research and the conduct of early and late-phase clinical trials, with a focus on the development of new endocrine approaches for the treatment of ER+/HER2- breast cancer. A notable area of research focus for Dr Goetz’s laboratory has been the study of tamoxifen pharmacogenetics. Emanating from this work he has led a team of investigators in the development of the tamoxifen metabolite Z-endoxifen for the treatment of ER+ breast cancer, including phase 1 and 2 clinical studies in the metastatic and early stage settings.

Dr Goetz has also co-led prospective “multi-omic” breast cancer studies, including the BEAUTY (Breast Cancer Genome-Guided Therapy) study (NCT02022202) and the PROMISE (Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor [HR]-Positive, Breast Cancer) study (NCT03281902). Based on their work on the BEAUTY study, Dr Goetz and the BEAUTY team received the 2019 Mayo Clinic Team Science Award.

In addition to his clinical and research roles, Dr Goetz is active in professional organizations. He currently serves on the National Cancer Institute Breast Cancer Steering Committee, the Translational Breast Cancer Research Consortium Steering Committee, and the Early Breast Cancer Trialists’ Collaborative Group Steering Committee. He also currently serves as vice-chair of the Academic & Community Cancer Research United Executive Committee.